Delivering Advanced Healthcare Solutions Through Research And Innovation To Improve The Quality Of Human Life

In The News

MeRes100 BRS - the World's First Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold - Shows Consistent Long-term Positive Safety With Consistent Low MACE rates and Zero Scaffold Stent

January 03, 2020

MeRes100 BRS - the World's First Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold - Shows Consistent Long-term Positive Safety With Consistent Low MACE rates and Zero Scaffold Stent

Meril's recently CE-approved MeRes100, used for the treatment of de-novo coronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rate of 1.87% at three years as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years.

In The News

TCT 2019: Low rate of MACE at 12 months with “world’s thinnest stent”

December 28, 2019

TCT 2019: Low rate of MACE at 12 months with “world’s thinnest stent”

K Sivaprasad (Govt TD Medical College, Alappuzha, India) reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA) yesterday that the Evermine 50 stent (Meril Life), which has a strut thickness of 50μm, is associated with a low rate of major adverse events (MACE) at 12 months.

In The News

Thin-Strut Bioresorbable Vascular Scaffold Shows Promise

December 27, 2019

Thin-Strut Bioresorbable Vascular Scaffold Shows Promise

The MeRes 100 thin-strut sirolimus-eluting bioresorbable scaffold, developed by Meril Life Sciences, demonstrated zero scaffold thrombosis and very low major adverse cardiac event rates for up to three years, according to two recent clinical trials.